Skip to main content
    Paid monthly and annual subscribers can read every Medi-Chi book online — including clinical references and the TCM Textbook · downloads sold separatelySee the libraryClinical Education Tool — This platform provides educational resources for TCM practitioners and students. It does not issue medical certificates, prescriptions, or clinical diagnoses.
    men's health

    Testicular cancer

    Also known as: Testicular malignancy, Cancer of the testis, Testicular carcinoma

    Testicular cancer demonstrates high rates of curability via specialist surgical intervention, chemotherapy, and radiotherapy, necessitating immediate urological evaluation and staging. Survivorship protocols focus on the mitigation of physical and psychological sequelae, fertility preservation, and rigorous long-term surveillance. Within a TCM framework, practitioners may employ adjunctive strategies to address fatigue, anorexia, psychological distress, and insomnia; however, a testicular mass must never be interpreted as a benign pattern. The cited evidence does not establish the efficacy of acupuncture or herbal medicine for oncological treatment or the management of treatment-related adverse effects. Experimental findings regarding molecular pathways, epidemiological trends, and murine models of nephroprotection do not currently translate to validated clinical benefits. Supportive interventions must be coordinated with the multidisciplinary oncology team and must not delay conventional diagnostic investigations, treatment, or surveillance.

    Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.

    All clinical details on this page are for practitioner premium subscribers only.
    Checking your practitioner access
    Verifying your Medi-Chi access…

    Lifestyle & Diet

    • •Prioritise all oncology surveillance, including diagnostic imaging and pathology appointments, regardless of perceived wellness.
    • •Consult the specialist multidisciplinary team early regarding fertility preservation, sexual dysfunction, and the management of potential endocrine changes.
    • •Maintain consistent nutritional intake and appropriate physical activity; request referral to a dietitian or exercise physiologist if anorexia or functional capacity declines.
    • •Maintain a comprehensive record of all pharmacological agents, herbs, and supplements, and ensure this list is reviewed by an oncology pharmacist prior to the commencement of any new substance.

    Cautions & Contraindications

    See sources
    • •Never needle or apply vigorous local treatment over the testis, a suspected tumour, an unhealed inguinal incision, infected skin or a vascular access device. These are general procedural precautions; record 4 supplies survivorship context, not acupuncture safety evidence.[]
    • •Defer acupuncture during febrile illness or clinical instability. With neutropenia, thrombocytopenia, anticoagulation or impaired healing, obtain oncology advice and follow local oncology acupuncture protocols; the supplied abstract provides no safe blood-count thresholds.[]
    • •Do not recommend hesperetin, selenium or fucoidan supplements as proven protection against cisplatin kidney injury. Record 3 tested a specific nanoparticle preparation in cells and mice, not patients, and does not establish supplement efficacy or safety.[]
    • •Do not start herbal formulas during chemotherapy, radiotherapy or the perioperative period without oncology-pharmacist review. General interaction and treatment-safety precaution; none of the supplied abstracts establishes the safety of these formulas alongside cancer treatment.[]

    When to reassess or seek care again

    See sources

    If supportive care is agreed, review after 2–4 weeks using fatigue and nausea scores from 0–10, sleep duration, appetite, weight trend and daily activity tolerance. Record adverse events at every visit. Stop and seek oncology review for worsening symptoms, new unexplained pain, weight loss or treatment toxicity; urgent findings require immediate escalation. If no meaningful symptom improvement by the review, reconsider rather than extending treatment automatically. Tumour response and recurrence monitoring remain solely with specialist care.

    Explore more diseases

    Sources & Further Reading

    Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.

    1. Endocrine, metabolic & immune disorders drug targets · 2026
    2. Frontiers in oncology · 2026
    3. Discover nano · 2026
    4. Journal of the advanced practitioner in oncology · 2026

    Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.